MorphoSys gains on updated response data for MOR208 in DLBCL

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) shares rose Thursday when it reported that MOR208 plus Revlimid lenalidomide led to a 58% overall response rate (ORR) among 81 evaluable patients with relapsed or refractory diffuse large B cell lymphoma in the Phase II L-MIND trial. The updated data were released in an abstract ahead of next month’s American Society of Hematology meeting. MorphoSys jumped €13.45 (16%) to €95.25 on Xetra Thursday, and added $4.16 (18%) to $27.18 on NASDAQ.

In March, MorphoSys reported that the combo led to an ORR of 49% in 68 evaluable patients. The company has said it plans to submit a rolling BLA to FDA in 2H19 for MOR208 (see "MorphoSys Planning BLA for DLBCL Candidate on Phase II Data")...